141 related articles for article (PubMed ID: 27330661)
21. Synthetic cannabinoid intoxication: a case series and review.
Harris CR; Brown A
J Emerg Med; 2013 Feb; 44(2):360-6. PubMed ID: 22989695
[TBL] [Abstract][Full Text] [Related]
22. In vitro Phase I metabolism of indazole carboxamide synthetic cannabinoid MDMB-CHMINACA via human liver microsome incubation and high-resolution mass spectrometry.
Presley BC; Logan BK; Jansen-Varnum SA
Drug Test Anal; 2019 Aug; 11(8):1264-1276. PubMed ID: 31108568
[TBL] [Abstract][Full Text] [Related]
23. Severe Illness Associated with Reported Use of Synthetic Cannabinoids - Mississippi, April 2015.
Kasper AM; Ridpath AD; Arnold JK; Chatham-Stephens K; Morrison M; Olayinka O; Parker C; Galli R; Cox R; Preacely N; Anderson J; Kyle PB; Gerona R; Martin C; Schier J; Wolkin A; Dobbs T
MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(39):1121-2. PubMed ID: 26447715
[TBL] [Abstract][Full Text] [Related]
24. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
Cairns R; Brown JA; Gunja N; Buckley NA
Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
[TBL] [Abstract][Full Text] [Related]
25. Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.
Khullar V; Jain A; Sattari M
J Gen Intern Med; 2014 Aug; 29(8):1200-4. PubMed ID: 24553958
[TBL] [Abstract][Full Text] [Related]
26. Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA.
Shanks KG; Clark W; Behonick G
J Anal Toxicol; 2016 Apr; 40(3):236-9. PubMed ID: 26755539
[TBL] [Abstract][Full Text] [Related]
27. Convulsions associated with the use of a synthetic cannabinoid product.
Schneir AB; Baumbacher T
J Med Toxicol; 2012 Mar; 8(1):62-4. PubMed ID: 22160733
[TBL] [Abstract][Full Text] [Related]
28. Case of brodifacoum-contaminated synthetic cannabinoid.
Riley SB; Sochat M; Moser K; Lynch KL; Tochtrop R; Isbell TS; Scalzo A
Clin Toxicol (Phila); 2019 Feb; 57(2):143-144. PubMed ID: 30148410
[No Abstract] [Full Text] [Related]
29. Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015.
Riederer AM; Campleman SL; Carlson RG; Boyer EW; Manini AF; Wax PM; Brent JA;
MMWR Morb Mortal Wkly Rep; 2016 Jul; 65(27):692-5. PubMed ID: 27413997
[TBL] [Abstract][Full Text] [Related]
30. Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study.
Monte AA; Calello DP; Gerona RR; Hamad E; Campleman SL; Brent J; Wax P; Carlson RG;
J Med Toxicol; 2017 Jun; 13(2):146-152. PubMed ID: 28397128
[TBL] [Abstract][Full Text] [Related]
31. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V
Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158
[TBL] [Abstract][Full Text] [Related]
32. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set.
Wolfe CE; Wood DM; Dines A; Whatley BP; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Dargan PI;
Neurotoxicology; 2019 Jul; 73():183-187. PubMed ID: 30974132
[TBL] [Abstract][Full Text] [Related]
33. ["Spice"--synthetic cannabinoids with dangerous effects].
Personne M; Westerbergh J; Hammer-Pettersen L
Lakartidningen; 2014 Nov; 111(47):2105-7. PubMed ID: 25386644
[TBL] [Abstract][Full Text] [Related]
34. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA.
Seywright A; Torrance HJ; Wylie FM; McKeown DA; Lowe DJ; Stevenson R
Clin Toxicol (Phila); 2016 Sep; 54(8):632-7. PubMed ID: 27213960
[TBL] [Abstract][Full Text] [Related]
35. A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis
El Zahran T; Gerona R; Morgan BW; Pomerleau AC
Clin Toxicol (Phila); 2019 Jun; 57(6):421-422. PubMed ID: 30442067
[No Abstract] [Full Text] [Related]
36. Hyperthermia , Rhabdomyolysis and Synthetic Cannabinoids - the authors respond.
Hassen GW; Kalantari H
Am J Emerg Med; 2016 Aug; 34(8):1691. PubMed ID: 27238851
[No Abstract] [Full Text] [Related]
37. Aspects related to analysis and medico-legal assessment in the context of the presence of synthetic cannabinoids in biological material based on the example of AB-CHMINACA.
Romańczuk A; Rojek S; Kula K; Kłys M
Arch Med Sadowej Kryminol; 2018; 68(4):266-280. PubMed ID: 31025844
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and circumstances of synthetic cannabinoid-related death.
Darke S; Duflou J; Farrell M; Peacock A; Lappin J
Clin Toxicol (Phila); 2020 May; 58(5):368-374. PubMed ID: 31389266
[No Abstract] [Full Text] [Related]
39. Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).
Kasper AM; Ridpath AD; Gerona RR; Cox R; Galli R; Kyle PB; Parker C; Arnold JK; Chatham-Stephens K; Morrison MA; Olayinka O; Preacely N; Kieszak SM; Martin C; Schier JG; Wolkin A; Byers P; Dobbs T
Clin Toxicol (Phila); 2019 Jan; 57(1):10-18. PubMed ID: 29989463
[TBL] [Abstract][Full Text] [Related]
40. Severe toxicity following synthetic cannabinoid ingestion.
Lapoint J; James LP; Moran CL; Nelson LS; Hoffman RS; Moran JH
Clin Toxicol (Phila); 2011 Oct; 49(8):760-4. PubMed ID: 21970775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
